ZA200603533B - CCI-779 for treating mantle cell lymphoma - Google Patents

CCI-779 for treating mantle cell lymphoma Download PDF

Info

Publication number
ZA200603533B
ZA200603533B ZA200603533A ZA200603533A ZA200603533B ZA 200603533 B ZA200603533 B ZA 200603533B ZA 200603533 A ZA200603533 A ZA 200603533A ZA 200603533 A ZA200603533 A ZA 200603533A ZA 200603533 B ZA200603533 B ZA 200603533B
Authority
ZA
South Africa
Prior art keywords
cci
cell lymphoma
mantle cell
rapamycin
use according
Prior art date
Application number
ZA200603533A
Other languages
English (en)
Inventor
Thomas E Witzig
Scott H Kaufmann
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200603533(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of ZA200603533B publication Critical patent/ZA200603533B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200603533A 2003-11-04 2006-05-03 CCI-779 for treating mantle cell lymphoma ZA200603533B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51732903P 2003-11-04 2003-11-04

Publications (1)

Publication Number Publication Date
ZA200603533B true ZA200603533B (en) 2007-07-25

Family

ID=34590151

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603533A ZA200603533B (en) 2003-11-04 2006-05-03 CCI-779 for treating mantle cell lymphoma

Country Status (30)

Country Link
US (2) US20050113403A1 (fr)
EP (1) EP1682131B9 (fr)
JP (1) JP4856548B2 (fr)
KR (1) KR101387988B1 (fr)
CN (1) CN1901906B (fr)
AR (1) AR046194A1 (fr)
AT (1) ATE373477T1 (fr)
AU (1) AU2004289213B2 (fr)
BR (1) BRPI0415714A (fr)
CA (1) CA2543665C (fr)
CO (1) CO5690605A2 (fr)
CR (1) CR8383A (fr)
DE (1) DE602004009098T2 (fr)
DK (1) DK1682131T3 (fr)
EC (1) ECSP066600A (fr)
ES (1) ES2291954T3 (fr)
GT (1) GT200400224A (fr)
IL (2) IL175128A0 (fr)
MY (1) MY136436A (fr)
NO (1) NO20062271L (fr)
PA (1) PA8616601A1 (fr)
PE (1) PE20051000A1 (fr)
PL (1) PL1682131T3 (fr)
PT (1) PT1682131E (fr)
RU (1) RU2358731C2 (fr)
SA (1) SA04250375B1 (fr)
TW (1) TW200517116A (fr)
UA (1) UA83697C2 (fr)
WO (1) WO2005046681A1 (fr)
ZA (1) ZA200603533B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
EP2097085A4 (fr) * 2006-11-27 2010-02-10 Ariad Pharma Inc Matériaux et procédés thérapeutiques
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
EP1319008B1 (fr) 2000-09-19 2008-10-15 Wyeth Esters de rapamycine hydrosolubles
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
EA007530B1 (ru) 2001-06-01 2006-10-27 Уайт Противоопухолевые комбинации
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
NZ537829A (en) * 2002-07-30 2006-09-29 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
ATE352301T1 (de) * 2003-04-22 2007-02-15 Wyeth Corp Antineoplastische zusammensetzungen
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab

Also Published As

Publication number Publication date
PT1682131E (pt) 2007-11-08
IL175128A0 (en) 2008-04-13
PE20051000A1 (es) 2006-02-03
AU2004289213A1 (en) 2005-05-26
ECSP066600A (es) 2006-10-25
KR20060111559A (ko) 2006-10-27
ATE373477T1 (de) 2007-10-15
AU2004289213B2 (en) 2010-08-26
ES2291954T3 (es) 2008-03-01
KR101387988B1 (ko) 2014-04-22
DE602004009098T2 (de) 2008-06-26
US8507518B2 (en) 2013-08-13
HK1088241A1 (en) 2006-11-03
US20110184010A1 (en) 2011-07-28
BRPI0415714A (pt) 2006-12-19
JP4856548B2 (ja) 2012-01-18
CN1901906B (zh) 2011-11-16
NO20062271L (no) 2006-07-21
EP1682131B1 (fr) 2007-09-19
GT200400224A (es) 2005-06-06
CN1901906A (zh) 2007-01-24
TW200517116A (en) 2005-06-01
DE602004009098D1 (de) 2007-10-31
CO5690605A2 (es) 2006-10-31
EP1682131A1 (fr) 2006-07-26
MY136436A (en) 2008-10-31
PL1682131T3 (pl) 2008-02-29
JP2007510721A (ja) 2007-04-26
DK1682131T3 (da) 2008-01-28
CR8383A (es) 2006-10-04
CA2543665A1 (fr) 2005-05-26
PA8616601A1 (es) 2006-06-02
WO2005046681A1 (fr) 2005-05-26
CA2543665C (fr) 2009-07-14
RU2006119451A (ru) 2007-12-20
RU2358731C2 (ru) 2009-06-20
AR046194A1 (es) 2005-11-30
US20050113403A1 (en) 2005-05-26
IL220080A0 (en) 2012-07-31
EP1682131B9 (fr) 2009-03-25
SA04250375B1 (ar) 2007-08-13
UA83697C2 (ru) 2008-08-11

Similar Documents

Publication Publication Date Title
RU2355399C2 (ru) Противоопухолевые композиции, содержащие производное рапамицина и ингибитор ароматазы
US7060709B2 (en) Method of treating hepatic fibrosis
CA2736361A1 (fr) Combinaison d'un inhibiteur de la phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor
US20040258662A1 (en) Antineoplastic agents
US8507518B2 (en) Method of treating mantle cell lymphoma
US8791097B2 (en) Anti-tumor activity of CCI-779 in papillary renal cell cancer
MXPA06004707A (en) Cci-779 for treating mantle cell lymphoma
HK1088241B (en) Cci-779 for treating mantle cell lymphoma
HK1226654A1 (en) Anti-tumor activity of temsirolimus in papillary renal cell cancer
HK1226654A (en) Anti-tumor activity of temsirolimus in papillary renal cell cancer
HK1142538A (en) Anti-tumor activity of temsirolimus in papillary renal cell cancer